Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.

Joanne L BlumA Douglas LairdJennifer K LittonHope S RugoJohannes EttlSara A HurvitzMiguel MartinHenri H RochéKyung-Hun Lee Annabel GoodwinYing ChenSilvana LanzaloneJijumon ChelliserryAkos CzibereJulia F HopkinsLee A Albacker Lida A Mina

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Overall, BRCA LOH status, DDR gene mutational burden, and gLOH were not associated with talazoparib efficacy; however, these conclusions are qualified by population heterogeneity and low patient numbers in some subgroups. Further investigation in larger patient populations is warranted.

Keyphrases

case report
breast cancer risk
single cell
dna repair
copy number
gene expression
transcription factor
dna damage
genetic diversity